U.S. Markets closed

Ardelyx, Inc. (ARDX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
6.31+0.27 (+4.47%)
At close: 1:00PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close6.04
Open6.00
Bid5.80 x 1000
Ask6.50 x 3100
Day's Range5.99 - 6.31
52 Week Range4.22 - 8.81
Volume306,143
Avg. Volume490,649
Market Cap569.468M
Beta (5Y Monthly)2.00
PE Ratio (TTM)N/A
EPS (TTM)-1.01
Earnings DateNov 05, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est13.00
  • Ardelyx to Present at the Piper Sandler 32nd Annual Virtual Healthcare Conference
    PR Newswire

    Ardelyx to Present at the Piper Sandler 32nd Annual Virtual Healthcare Conference

    Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company focused on developing innovative first-in-class medicines to improve treatment for people with kidney and cardiovascular diseases, today announced that a webcast of Mike Raab, president and chief executive officer of Ardelyx, and Susan Rodriguez, chief commercial officer, participating in a fireside chat at the Piper Sandler 32nd Annual Virtual Healthcare Conference will be available today at 10 a.m. ET.

  • Ardelyx to Present at the Jefferies Virtual London Healthcare Conference
    PR Newswire

    Ardelyx to Present at the Jefferies Virtual London Healthcare Conference

    Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company focused on developing innovative first-in-class medicines to improve treatment for people with kidney and cardiovascular diseases, today announced that Mike Raab, president and chief executive officer of Ardelyx, will participate in a fireside chat at the Jefferies Virtual London Healthcare Conference on Tuesday, November 17, 2020 at 1:10 p.m. ET.

  • Ardelyx to Webcast Virtual Analyst Day
    PR Newswire

    Ardelyx to Webcast Virtual Analyst Day

    Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company focused on developing first-in-class medicines to improve treatment for people with kidney and cardiovascular diseases, today announced that it will hold a virtual Analyst Day on Thursday, November 12, 2020, from 9:30 a.m. to 12:00 p.m. ET. This year's event will focus on the company's launch and commercialization plans in anticipation of the potential approval of tenapanor for the control of serum phosphorus in adult patients with chronic kidney disease (CKD) on dialysis. Additionally, the company will review its pipeline therapeutic for hyperkalemia.